Global Oncology | Specialty

The OncLive® Global Oncology condition center page is a comprehensive resource for clinical news and international expert insights on treatment of patients with cancer. This page features articles focused on ex-US regulatory news, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing global research in oncology care.

Mirdametinib Earns Positive CHMP Opinion for NF1-Associated Plexiform Neurofibromas

May 23rd 2025

The EMA’s CHMP has issued a positive opinion for mirdametinib for pediatric and adult patients with NF1-associated plexiform neurofibromas.

Artificial Intelligence Proves Its Worth in Cancer Treatment, Drug Development, and Other Real-World Applications

May 22nd 2025

Multiple experts on artificial intelligence in cancer care discuss its ever-expanding role in several areas of oncology.

Health Canada Approves Osimertinib for Locally Advanced, Unresectable EGFR+ NSCLC After Chemoradiation

May 22nd 2025

Osimertinib, with conditions, has been approved by Health Canada for locally advanced, unresectable NSCLC, harboring EGFR mutations.

China’s NMPA Approves Tafasitamab Plus Lenalidomide in Transplant-Ineligible R/R DLBCL

May 21st 2025

Tafasitamab plus lenalidomide has received NMPA approval for patients with relapsed/refractory DLBCL who are ineligible for ASCT.

Belantamab Mafodotin–Based Combos Win Japanese Approval for R/R Myeloma

May 19th 2025

Two belantamab mafodotin–based combinations have been approved in Japan for relapsed/refractory multiple myeloma.

Cemiplimab Displays Survival Benefits Over Chemotherapy in First-Line Advanced PD-L1–High NSCLC With Brain Metastases

May 17th 2025

First-line cemiplimab extended median PFS and OS vs chemotherapy in patients with untreated advanced NSCLC with brain metastases.

Bireociclib Earns NMPA Approval in China For 2 Indications in HR+/HER2– Breast Cancer

May 16th 2025

China’s NMPA approved bireociclib for 2 indications in adult patients with HR+/HER2– breast cancer.

European Commission Approves Perioperative Nivolumab and Chemotherapy for Resectable PD-L1+ NSCLC

May 16th 2025

Perioperative nivolumab plus chemotherapy was approved by the European Commission for use in resectable PD-L1–positive non–small cell lung cancer.

Piflufolastat (18F) Wins Approval in Switzerland for Detecting PSMA+ Lesions in Prostate Cancer

May 13th 2025

Switzerland has approved piflufolastat (18F) as an imaging agent to detect PSMA-positive lesions in prostate cancer.

Capecitabine/Bevacizumab Yields Antitumor Activity and a Favorable Safety Profile in Older mCRC Population

May 13th 2025

Capecitabine/bevacizumab had favorable efficacy and safety profiles among older patients with metastatic colorectal cancer.

Frontline Disitamab Vedotin Plus Toripalimab Improves PFS and OS in HER2+ Metastatic Urothelial Carcinoma

May 12th 2025

Disitamab vedotin plus toripalimab improved PFS and OS vs chemotherapy in HER2-expressing metastatic urothelial carcinoma.

Patients With Progressive CLL After Zanubrutinib or Ibrutinib Therapy Often Do Not Have BTK-Mutated Disease

May 11th 2025

BTK mutations occurred at low rates in patients with CLL who had disease progression after receiving zanubrutinib or ibrutinib in the phase 3 ALPINE study.

Illuccix PSMA-PET Imaging Kit Earns Czech Marketing Authorization in Prostate Cancer

May 9th 2025

The Czech Republic’s State Institute for Drug Control has approved the Illuccix PSMA-PET imaging kit in adult patients with prostate cancer.

SCG101 Shows Antiviral and Antitumor Activity in Advanced HBV-Related HCC

May 8th 2025

SCG101 T-cell therapy was safe and induced sustained HBV clearance and antitumor activity in patients with advanced HBV-related hepatocellular carcinoma.

Acalabrutinib Plus BR Wins EU Approval for Previously Untreated, Transplant-Ineligible Mantle Cell Lymphoma

May 6th 2025

The European Commission has approved acalabrutinib plus bendamustine and rituximab for previously untreated, transplant-ineligible mantle cell lymphoma.

Zurletrectinib Receives Priority Review from NMPA for NTRK Gene Fusion+ Advanced Solid Tumors

May 2nd 2025

A priority review was granted to zurletrectinib in China for the treatment of patients with NTRK gene fusion–positive advanced solid tumors.

CHMP Recommends Approval of At-Home, Subcutaneous Trastuzumab/Pertuzumab in HER2+ Breast Cancer

April 30th 2025

The EMA’s CHMP has recommended at-home administration of pertuzumab, trastuzumab and hyaluronidase combination therapy for HER2+ breast cancer.

Acalabrutinib/Venetoclax With or Without Obinutuzumab Earns Positive CHMP Opinion for Untreated CLL

April 29th 2025

The EMA’s CHMP has recommended the approval for acalabrutinib/venetoclax with or without obinutuzumab in untreated CLL.

Ivonescimab Wins NMPA Approval in China for First-Line, PD-L1+ Advanced NSCLC

April 28th 2025

China’s NMPA approved ivonescimab for the first-line treatment of PD-L1–positive advanced non–small cell lung cancer.

Linvoseltamab Receives EC Approval for Heavily Pretreated R/R Myeloma

April 28th 2025

Linvoseltamab earned EC approval for relapsed/refractory multiple myeloma after at least 3 prior lines of therapy.